Rosito S,Nicchia G P,Palazzo C,et al. Supramolecular aggregation of aquaporin-4 is different in muscle and brain: correlation with tissue susceptibility in neuromyelitis optica[J]. J Cell Mol Med, 2018,22(2):1236-1246.
[3]
Steenwinkel F,Dolhain R,Hazes J,et al. Does prednisone use or disease activity in pregnant women with rheumatoid arthritis influence the body composition of their offspring?[J]. ReprodToxicol, 2017,71:118-123.
[4]
Ost L,Wettrell G,Björkhem I,et al.Prednisolone excretion in human milk[J].J Pediatr, 1985,106(6):1008-1011.
[5]
Colpo A,Marson P,Pavanello F,et al. Therapeutic apheresis during pregnancy: a single center experience[J]. Transfus Apher Sci, 2019,58(5):652-658.
[6]
Lipphardt M,Mühlhausen J,Kitze B,et al. Immunoadsorption or plasma exchange in steroid-refractory multiple sclerosis and neuromyelitis optica[J]. J Clin Apher, 2019,34(4):381-391.
[7]
Kaplan T B. Management of demyelinating disorders in pregnancy[J]. Neurol Clin, 2019,37(1):17-30.
[8]
Achiron A,Kishner I,Dolev M,et al.Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis[J]. J Neurol, 2004,251(9):1133-1137.
[9]
Matsumoto Y,Tsuchiya M,Norshalena S,et al. Severe aquaporin 4-IgG-positive neuromyelitis optica with disseminated herpes zoster in a pregnant woman successfully treated with intravenous immunoglobulin[J]. Mult Scler J Exp Tra, 2018,4(1):173-187.
[10]
Mahadevan U, Long M D, Kane S V, et al. Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease[J]. Gastroenterology, 2021,160(4):1131-1139.
[11]
Polifka J E,Friedman J M.Teratogen update: azathioprine and 6-mercaptopurine[J].Teratology, 2002,65(5):240-261.
[12]
Boer N K,Jarbandhan S V,Graaf P, et al. Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites[J]. Am J Gastroenterol, 2006,101(6):1390-1392.
[13]
Chen B,Wu Q,Ke G,et al.Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder[J]. Sci Rep, 2017,7(1):831.
[14]
Bramham K,Chusney G,Lee J,et al.Breastfeeding and tacrolimus: serial monitoring in breast-fed and bottle-fed infants[J]. Clin J Am Soc Nephrol, 2013,8(4):563-567.
[15]
Hebert M F,Zheng S,Hays K,et al. Interpreting tacrolimus concentrations during pregnancy and postpartum[J]. Transplantation, 2013,95(7):908-915.
[16]
Vaidyanathan A,McKeever K,Anand B,et al. Developmental immunotoxicology assessment of rituximab in cynomolgus monkeys[J]. Toxicol Sci, 2011,119(1):116-125.
[17]
Kümpfel T,Thiel S,Meinl I,et al.Anti-CD20 therapies and pregnancy in neuroimmunologicdisorders:a cohort study from Germany[J]. Neurol Neuroimmunol Neuroinflamm, 2021,8(1):e913
[18]
Bragnes Y, Boshuizen R, de Vries A, et al. Low level of rituximab in human breast milk in a patient treated during lactation[J]. Rheumatology (Oxford), 2017,56(6):1047-1048.
[19]
Cree B, Bennett J L, Kim H J, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum):adouble-blind, randomised placebo-controlled phase 2/3 trial[J].Lancet, 2019,394(10206):1352-1363.
[20]
Frampton J E. Inebilizumab: first approval[J]. Drugs, 2020,80(12):1259-1264.
Oreja G C, Wray S, Buffels R, et al. Pregnancy outcomes in patients treated with ocrelizumab[J]. J Neurol Sci, 2019,405:311-312.
[23]
Maillart E,Renaldo F,Papeix C, et al.Dramatic efficacy of ofatumumab in refractory pediatric-onset AQP4-IgG neuromyelitis optica spectrum disorder[J]. Neurol NeuroimmunolNeuroinflamm, 2020,7(3)
[24]
WeberS C, Schaefer C. Pregnancy outcome after tocilizumab therapy in early pregnancy-a case series from the German Embryotox Pharmacovigilance Center[J]. Reprod Toxicol, 2016,60:29-32.
[25]
Nakajima K,Watanabe O,Mochizuki M,et al.Pregnancy outcomes after exposure to tocilizumab: a retrospective analysis of 61 patients in Japan[J]. Mod Rheumatol, 2016,26(5):667-671.
[26]
Mao D Y, Thiel S, Mills E A, et al. Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations[J]. Nat Rev Neurol, 2020,16(3):154-170.
[27]
Sarno L, Tufano A, Maruotti G M, et al.Eculizumab in pregnancy: a narrative overview[J].J Nephrol, 2019,32(1):17-25.
[28]
Kelly R J,Höchsmann B,Szer J, et al.Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria[J]. N Engl J Med, 2015,373(11):1032-1039.
[29]
Hacohen Y,Rossor T,Mankad K,et al.'Leukodystrophy-like' phenotype in children with myelin oligodendrocyte glycoprotein antibody-associated disease[J]. Dev Med Child Neurol, 2018,60(4):417-423.
[30]
Baumann M,Sahin K,Lechner C,et al.Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein[J]. J Neurol Neurosurg Psychiatry, 2015,86(3):265-272.
Tenembaum S, Yeh E A. Pediatric NMOSD: a review and position statement on approach to work-up and diagnosis[J]. Front Pediatr, 2020,8:339.
[33]
Wong Y, Hacohen Y, Armangue T, et al. Paediatric acute disseminated encephalomyelitis followed by optic neuritis: disease course, treatment response and outcome[J]. Eur J Neurol, 2018,25(5):782-786.
Huang W, Wang L, Zhang B, et al. Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: a systematic review and network meta-analysis[J]. Mult Scler Relat Disord, 2019,35:246-252.
[36]
Durozard P,Rico A,Boutiere C,et al.Comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases[J]. Ann Neurol, 2020,87(2):256-266.
[37]
Duchow A, Bellmann S J.Satralizumab in the treatment of neuromyelitis optica spectrum disorder[J]. Neurodegener Dis Manag, 2021,11(1):49-59.
[38]
Cai L J,Zhang Q,Zhang Y,et al.Clinical characteristics of very late-onset neuromyelitis optica spectrum disorder[J]. Mult Scler Relat Disord, 2020,46:102515.
Ringelstein M,Ayzenberg I,Harmel J,et al. Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder[J]. JAMA Neurol, 2015,72(7):756-763.
[43]
Yamamura T,Kleiter I,Fujihara K,et al.Trial of satralizumab in neuromyelitis optica spectrum disorder[J].N Engl J Med, 2019,381(22):2114-2124.
[44]
Wingerchuk D M,Fujihara K,Palace J,et al. Long-term safety and efficacy of eculizumab in aquaporin-4 igg-positive NMOSD[J].Ann Neurol, 2021,89(6):1088-1098.
[45]
Fragoso Y D, Ruocco H H, Dias R M,et al. Late onset of neuromyelitis optica spectrum disorders[J].Neurol Ther, 2019,8(2):477-482.
2023, Vol. 34 
